MET Pathway as a Therapeutic Target
- 1 April 2009
- journal article
- review article
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 4 (4), 444-447
- https://doi.org/10.1097/jto.0b013e31819d6f91
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Paxillin Is a Target for Somatic Mutations in Lung Cancer: Implications for Cell Growth and InvasionCancer Research, 2008
- MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibProceedings of the National Academy of Sciences, 2007
- Experimental validation of miRNA targetsMethods, 2007
- Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasionBritish Journal of Cancer, 2007
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 2007
- The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variantsOncogene, 2004
- A switch from p130Cas/Crk to Gab1/Crk signaling correlates with anchorage independent growth and JNK activation in cells transformed by the Met receptor oncoproteinOncogene, 2000
- Differential signaling by alternative HGF isoforms through c-Met: activation of both MAP kinase and PI 3-kinase pathways is insufficient for mitogenesisOncogene, 1999
- Increasing levels of MYC and MET co-amplification during tumor progression of a case of gastric cancerCancer Genetics and Cytogenetics, 1995
- Identification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene ProductScience, 1991